LEGN: Three White Soldiers detected on 16 Oct 2026

LEGN is forming a three white soldiers pattern at $19.80, following a prior bullish pennant (21 days old, pattern quality 27). The setup scores 76 overall with solid structure (15/15) and breakout intensity (13/13), though volume is subdued at 9/12 with current volume 72% of the 20-day average. The pattern sits between key support at $16.86 and resistance at $22.05, positioned 21.92% above the 52-week low but 47.2% below the 52-week high. RSI at 55.33 shows neutral momentum; the measured move target is $20.84.

Legend Biotech reported strong Q2 2026 results with CARVYKTI net trade sales of $657 million (50% YoY growth) and $33.2 million net income versus a $125.4 million loss a year earlier. Most recently, preliminary Q3 2026 CARVYKTI sales reached $710 million, demonstrating continued commercial momentum. The company also achieved FDA clearance for LB2501, its CD19/CD20 in vivo CAR-T candidate, enabling a Phase 1/2 trial. Leadership transitioned when Ingrid Zhang became CEO on September 15, 2026. However, Barclays recently lowered its price target to $68 while maintaining an Overweight rating, and insider selling activity totaled $308,550 in recent months, signaling caution despite strong sales. The biotechnology sector regime is bullish (0.95 score), providing tailwinds.

A successful breakout above the $22.05 resistance would target $20.84 conservatively, with the pattern suggesting potential for continued upside if volume increases above the 20-day average. Historical data indicates a 59.41% win probability for this three white soldiers pattern. The setup fails if price closes decisively below the $16.86 key support level, which would negate the bullish structure and suggest return to prior downtrend. Volume confirmation above 2.17 million shares (20-day average) would strengthen confidence in breakout conviction.

Several headwinds merit attention. Insider selling of $308,550 in recent quarters and mixed guru positioning (one added, two trimmed holdings) suggest internal concerns despite strong CARVYKTI sales. Volume is currently suppressed at 72% of average, potentially indicating weak participation in the breakout attempt. The stock is down 11.05% over three months despite recent weekly strength, reflecting prior skepticism. Janssen dependency for CARVYKTI manufacturing and reporting creates operational risk; any supply chain disruption could impair revenue recognition. Barclays' price target reduction to $68 occurred recently, signaling analyst caution on near-term valuation. The healthcare sector beta of 0.26 is low, limiting upside leverage, and atr at 4.7% reflects moderate volatility.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.